Serplulimab and neoadjuvant therapy

Phase 2Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Serplulimab and neoadjuvant therapy is one of 46 small molecule programs targeting Peritoneal Metastases. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peritoneal MetastasesRecruiting

Lung CancerActive, not recruiting

Peritoneal MetastasesPhase 2

Recruiting

Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Tagrisso

AstraZeneca

Phase 3

19 3

Beyfortus

BeiGene

Phase 3

10 4

Abraxane

Bristol-Myers Squibb

Phase 3

7 5

Alecensa

Roche

Phase 3

3 6

DATROWAY

Daiichi Sankyo

Phase 3

2 7

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 8

Tarlatamab-Dznl

Amgen

Phase 3

2 9

Ilaris

Novartis

Phase 3

2 10

Verzenio

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Peritoneal Metastases

NCT05742425

Q4 2030

Phase 2Active, not recruiting

Lung Cancer

NCT05882513

Clinical

Trials by Indication[1]

Peritoneal Metastases1 trial

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05742425·30 enrolled

Lung Cancer1 trial

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05882513·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Serplulimab and neoadjuvant therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Serplulimab and neoadjuvant therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Serplulimab and neoadjuvant therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Serplulimab and neoadjuvant therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2030

Trials by Indication[1]

Peritoneal Metastases1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News